We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+2.07%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$833M
AUM Growth
-$400M
(-32%)
Cap. Flow
-$300M
Cap. Flow
% of AUM
-35.99%
Top 10 Holdings %
Top 10 Hldgs %
56.65%
Holding
156
New
48
Increased
29
Reduced
27
Closed
47
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$25M |
| 2 |
CELG
Celgene Corp
CELG
|
+$22.9M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$21.2M |
| 4 |
MacroGenics
MGNX
|
+$18.8M |
| 5 |
MannKind Corp
MNKD
|
+$17.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$144M |
| 2 |
ONXX
ONYX PHARMACEUTICALS INC
ONXX
|
+$69.5M |
| 3 |
Gilead Sciences
GILD
|
+$56.7M |
| 4 |
RPRX
Repros Therapeutics Inc.
RPRX
|
+$26.6M |
| 5 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.14% |
| 2 | Consumer Discretionary | 0.05% |
| 3 | Industrials | 0.03% |
| 4 | Consumer Staples | 0% |
| 5 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $86M | 10.33% |
1,018,400
+289,162
| +40% | +$22.9M |
|
2
Talphera
TLPH
$67.5M
| $74.4M | 8.93% |
328,703
+35,783
| +12% | +$6.22M |
|
|
3
Sarepta Therapeutics
SRPT
$1.62B
| $71M | 8.53% |
3,484,579
+712,510
| +26% | +$21.2M |
|
|
4
Vertex Pharmaceuticals
VRTX
$124B
| $60.3M | 7.24% |
811,728
+359,633
| +80% | +$25M |
|
|
TSRO
5
DELISTED
TESARO, Inc.
TSRO
| $40.9M | 4.91% |
1,446,570
-67,074
| -4% | -$2.49M |
|
6
Neurocrine Biosciences
NBIX
$18.3B
| $39.1M | 4.69% |
4,183,737
-86,967
| -2% | -$849K |
|
|
AEGR
7
DELISTED
Aegerion Pharmaceuticals
AEGR
| $31.8M | 3.82% |
447,785
-1,880,556
| -81% | -$144M |
|
|
COV
8
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
| $25.5M | 3.07% |
374,826
+163,581
| +77% | +$10.6M |
|
|
EXAS
9
DELISTED
Exact Sciences
EXAS
| $23M | 2.77% |
1,969,903
+221,589
| +13% | +$2.54M |
|
|
10
MannKind Corp
MNKD
$1.21B
| $19.8M | 2.37% |
759,000
+701,100
| +1,211% | +$17.8M |
|
|
11
MacroGenics
MGNX
$234M
| $19.7M | 2.36% |
+717,705
| New | +$18.8M |
|
|
WBA
12
DELISTED
Walgreens Boots Alliance
WBA
| $18.5M | 2.22% |
322,000
+134,130
| +71% | +$7.8M |
|
13
AbbVie
ABBV
$471B
| $18.5M | 2.22% |
+350,000
| New | +$17.2M |
|
|
DYAX
14
DELISTED
DYAX CORPORATION
DYAX
| $17.6M | 2.11% |
2,332,674
+639,762
| +38% | +$4.86M |
|
|
NEPT
15
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
| $17.1M | 2.06% |
4,215
+369
| +10% | +$1.55M |
|
16
Viatris
VTRS
$20.8B
| $17M | 2.05% |
392,500
-67,805
| -15% | -$2.79M |
|
17
Xencor
XNCR
$1.44B
| $14.3M | 1.72% |
+1,568,672
| New | +$13.5M |
|
18
Incyte
INCY
$25.3B
| $13.6M | 1.63% |
+268,800
| New | +$11.7M |
|
|
19
PUT
Sarepta Therapeutics
SRPT
$1.62B
| $13.2M | 1.59% |
+650,000
| New | +$19.3M |
|
20
Biogen
BIIB
$31.8B
| $11.2M | 1.34% |
+40,000
| New | +$10.3M |
|
21
Cigna
CI
$78.9B
| $10.9M | 1.31% |
125,000
-97,848
| -44% | -$8.01M |
|
|
SPNC
22
DELISTED
Spectranetics Corp
SPNC
| $8.66M | 1.04% |
346,254
+192,175
| +125% | +$4.12M |
|
|
RLYP
23
DELISTED
RELYPSA INC COM
RLYP
| $8.53M | 1.02% |
+341,200
| New | +$7.01M |
|
|
ANAC
24
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $8.18M | 0.98% |
487,542
-486,326
| -50% | -$6.73M |
|
|
HNT
25
DELISTED
HEALTH NET INC
HNT
| $8.09M | 0.97% |
272,775
-181,005
| -40% | -$5.42M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Perceptive Advisors held 156 positions worth $833M, down 32% from $1.23B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Perceptive Advisors withdrew a net $300M in Q4 2013, closing 47 positions and reducing 27 holdings. Its most notable exit was ONYX PHARMACEUTICALS INC, an estimated $69.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 77% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Perceptive Advisors opened a new position in MacroGenics worth $19.7M.
- Perceptive Advisors's largest Q4 2013 buy was MacroGenics: 717,705 shares worth $19.7M.
- Perceptive Advisors added most to Vertex Pharmaceuticals in Q4 2013, an estimated $25M increase.
- Perceptive Advisors's biggest Q4 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $144M.
- Perceptive Advisors fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $69.5M.
- Perceptive Advisors's ten largest holdings make up 57% of its $833M portfolio in Q4 2013.
- Perceptive Advisors opened 48 new positions and closed 47 in Q4 2013.
- Perceptive Advisors's portfolio value fell 32% quarter-over-quarter to $833M.
Based on Perceptive Advisors's 13F filing for Q4 2013, filed 14 Feb 2014.